American Society of Hematology : Congress Essentials

December 6–9, 2025 | Orlando, United States

American Society of Hematology

Date: December 6–9, 2025
Exhibit location:

Orange County Convention Center
9800 International Dr.
Orlando, FL 32819
Booth:

Booth #409
Saturday, Dec 6: 11 AM to 5 PM EST
Sunday, Dec 7: 10 AM to 5 PM EST
Monday, Dec 8: 10 AM to 2 PM EST

Key Data Presentations

Final analysis of the randomized phase 2 ROSEWOOD study of zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma

ASH 2025 FL Zanubrutinib

Pier Luigi Zinzani

FIND OUT MORE

Sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) previously treated with a Bruton tyrosine kinase (BTK) inhibitor: Early results from a phase 1/2 study

ASH 2025 MCL BGB-11417, Sonrotoclax

Michael Wang

FIND OUT MORE

Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Results from the ALPINE trial

ASH 2025 CLL/SLL

Jennifer R. Brown

FIND OUT MORE

Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) with continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study

ASH 2025 CLL/SLL Zanubrutinib

Constantine S. Tam

FIND OUT MORE

Long-term results of patients receiving zanubrutinib in the phase 3 ALPINE study confirm sustained benefit of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL): Up to 6 years of follow-up with the long-term extension (LTE1)

ASH 2025 CLL/SLL Zanubrutinib

Constantine S. Tam

FIND OUT MORE

Zanubrutinib + venetoclax for treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including patients with del(17p) and/or TP53 mutation and unmutated immunoglobulin heavy-chain variable status: 3 year results from SEQUOIA arm D

ASH 2025 CLL/SLL Zanubrutinib

Mazyar Shadman

FIND OUT MORE

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

ASH 2025 CLL/SLL Tacabrutideg

Meghan C. Thompson

FIND OUT MORE

Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study

ASH 2025 CLL/SLL BGB-11417, Sonrotoclax, Zanubrutinib

Constantine S. Tam

FIND OUT MORE

Number needed to treat to avoid progression or death: Zanubrutinib vs other covalent Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia

ASH 2025 CLL Zanubrutinib

Mazyar Shadman

FIND OUT MORE

Evaluation of factors from established prognostic models in patients with chronic lymphocytic leukemia (CLL) treated with zanubrutinib: A post-hoc analysis of two phase 3 studies (SEQUOIA and ALPINE)

ASH 2025 CLL Zanubrutinib

Inhye E. Ahn

FIND OUT MORE

Treatment patterns and outcomes among patients treated with second-generation BTK inhibitors in CLL

ASH 2025 CLL Zanubrutinib

Aryan Ayati

FIND OUT MORE

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

ASH 2025 DLBCL Zanubrutinib

Li Wang

FIND OUT MORE

Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies: A long-term follow-up

ASH 2025 B-cell malignancies Zanubrutinib

Mazyar Shadman

FIND OUT MORE

Outcomes during BTKi treatment for chronic lymphocytic leukemia: Insights from remote therapeutic monitoring

ASH 2025 CLL

Gurjyot Doshi

FIND OUT MORE

American Society of Hematology : Congress Essentials